close

BioDelivery Sciences International, Inc. operates as a specialty pharmaceutical company in the United States. Its patented drug delivery technologies include BEMA drug delivery technology and Bioral cochleate drug delivery technology. The company, using its drug delivery technologies, develops formulations of pharmaceuticals aimed principally at short term acute conditions occurring in patients, primarily in the areas of pain and fungal infections. Its lead product is ONSOLIS, a treatment for pain in opioid tolerant patients with cancer. BioDelivery Sciences licensed the commercialization and distribution rights for ONSOLIS to Meda AB. The company's products/formulations also include BEMA Buprenorphine, which is under preparation for phase 2 for moderate to severe and acute pain. Its lead Bioral formulation is an encochleated version of Amphotericin B, an anti-fungal treatment for systemic fungal infections. The company also has a Bioral formulation, which is in initial in vitro studies for the intranasal administration of Amphotericin B to treat chronic rhinosinusitis. BioDelivery Sciences has a research collaboration and licensing agreement with the Drugs for Neglected Diseases initiative (DNDi) to develop Bioral Amphotericin B for the treatment of neglected diseases, such as leishmaniasis and Chagas disease. The company was founded in 1997 and is based in Raleigh, North Carolina.

(login to add this stock to your watchlist or favorites)

Key Statistics

Closing Price	2.24
Volume	39648
Volume Avg	319192
52 Week High	4.05
52 Week Low	0.77
PE	N/A
PE (group average)	39
EPS Year	-0.99
EPS change Q/Q	-19.23%
EPS change Q/Q Yr ago	1000%
EPS change Q/Q next Q est	1000%
EPS change Y/Y	-1000%
REV change Q/Q	250%
REV change Q/Q Yr ago	-98.89%
EPS next Q est	0.60
EPS next Y est	0.05
Divident Annual	0.00
Dividend Yield	0%